TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33387550
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 18 μg epinephrine
Study: 32726445
Drug: Increasing quantities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing quantities of L crispatus
Study: 32467299
Drug: IL-2 monotherapy
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 monotherapy
Study: 36410471
Drug: Ripasudil-brimonidine fixed-dose
Normalized name: brimonidine and ripasudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ripasudil-brimonidine fixed-dose combination (RBFC)
Study: 34447181
Drug: aceclofenac +
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aceclofenac + paracetamol
Study: 33954780
Drug: HPHF meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPHF meal (60 g protein, 40 g fat)
Study: 33954780
Drug: LPLF meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPLF meal (5 g protein, 5 g fat)
Study: 37062416
Drug: Nab-paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (125 mg/m2 q1w)
Study: 34305238
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of bupivacaine, 3 μg of sufentanil, and 10 μg of dexmedetomidine
Study: 34742002
Drug: Multisystemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy - Building Stronger Families (MST-BSF)
Study: 34742002
Drug: Comprehensive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Community Treatment (CCT)
Study: 33576415
Drug: Integrated Psychosocial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychosocial Group Treatment (IPGT)
Study: 616391466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biperiden and ATD
Study: 37533380
Drug: Trazpiroben 5
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 5 mg
Study: 37533380
Drug: Trazpiroben 25
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 25 mg
Study: 34967147
Drug: Trazpiroben 100
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 100 mg
Study: 36762852
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy
Study: 32301670
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment on the upper eyelid
Study: 32301670
Drug: Normal IPL
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal IPL treatment
Study: 32232659
Drug: Continuous quadratus
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous quadratus lumborum block (QLB) with 0.25% levobupivacaine 30 ml
Study: 34491646
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with medication
Study: 98049290
Drug: Tolbutamide (0.74
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide (0.74 mg. m<sup>‐2</sup>. min<sup>‐</sup> <sup>1</sup>)
Study: 98049290
Drug: Tolbutamide (elevated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide (elevated both peripheral and portal insulin concentrations)
Study: 98049290
Drug: Somatostatin (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (concurrent administration to inhibit tolbutamide-stimulated insulin secretion)
Study: 33939649
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine citrate infusion (200 mg)
Study: 32015031
Drug: CSJ148 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSJ148 (combination of LJP538 and LJP539)
Study: 32066666
Drug: Bumetanide treatment
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide treatment (0.5 mg twice daily)
Study: 32066666
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bumetanide treatment)
Study: 33011399
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of photodynamic therapy (PDT) with scaling and root planing (SRP)
Study: 33011399
Drug: Two sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sessions of photodynamic therapy (PDT) with scaling and root planing (SRP)
Study: 33011399
Drug: Three sessions
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sessions of photodynamic therapy (PDT) with scaling and root planing (SRP)
Study: 36331099
Drug: 0.1% bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bromfenac (BF) ophthalmic solution
Study: 33758395
Drug: Surfactant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant therapy
Study: 34844575
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) - eight 2-hour sessions
Study: 35144620
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg once daily for 8 days
Study: 33386953
Drug: Late-ZOL (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-ZOL (18 months after last Dmab injection)
Study: 33208696
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: No medication (control group)
Study: 35169872
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy on alternate days at 33 different sites of the oral mucosa (1 J for 10 s per application point) using a low-power aluminum gallium arsenide laser device (max output power 86.7 mW, wavelength 660 nm)
Study: 37060420
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy
Study: 36116481
Drug: Dupilumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (200 mg for bodyweight ≥5 kg to <15 kg; 300 mg for bodyweight ≥15 kg to <30 kg) every 4 weeks plus low-potency topical corticosteroids (hydrocortisone acetate 1% cream) for 16 weeks
Study: 35802749
Drug: IL-MA injections
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-MA injections once a week
Study: 35802749
Drug: IL-MA injections
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-MA injections twice a week
Study: 34809666
Drug: Supervised high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised high-intensity functional exercise programme (HIFE) executed twice weekly over 12 weeks
Study: 34402360
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined estradiol 0.5 mg + dydrogesterone 2.5 mg
Study: 34540991
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage administered 2 hours before endoscopy
Study: 34540991
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage administered 4 hours before endoscopy
Study: 33848338
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC and 0.12 mg CBD daily (Treatment B)
Study: 33848338
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg THC and 0.18 mg CBD daily (Treatment C)
Study: 33848338
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg THC and 0.24 mg CBD daily (Treatment D)
Study: 33848338
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B vs Treatment D
Study: 32663286
Drug: App-based mindfulness-meditation
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based mindfulness-meditation program (10 min daily for 30 days)
Study: 32023539
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (5,000 IU daily for 12 weeks)
Study: 38186268
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy
Study: 39773838
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs)
Study: 36058201
Drug: Cortisol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (10 mg hydrocortisone)
Study: 36151864
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (apremilast 10 mg to 60 mg + phototherapy)
Study: 33918724
Drug: BMGIM music
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMGIM music therapy (8 sessions over 8 weeks)
Study: 34323984
Drug: Clinician-facing intervention
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-facing intervention providing information about patient analgesic treatment preference and risk of opioid misuse.
Study: 35889747
Drug: Oral Arthrospira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Arthrospira at 3 g daily
Study: 35889747
Drug: Oral Arthrospira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Arthrospira at 6 g daily
Study: 32843164
Drug: IND/GLY/MF high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY/MF high-dose (150/50/160 μg) once-daily
Study: 32843164
Drug: IND/GLY/MF medium-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY/MF medium-dose (150/50/80 μg) once-daily
Study: 36429797
Drug: Directed vestibular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed vestibular rehabilitation therapy (VRT) plus manual therapy (MT) once a week for 4 weeks
Study: 36429797
Drug: Directed vestibular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed vestibular rehabilitation therapy (VRT)
Study: 36429797
Drug: Directed vestibular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed vestibular rehabilitation therapy (VRT) plus manual therapy (MT)
Study: 37656441
Drug: Cytotoxic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic chemotherapy
Study: 34599466
Drug: Lactulose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (10 g)
Study: 35578445
Drug: Pioglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone monotherapy
Study: 39103966
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT)
Study: 34717700
Drug: LOV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOV group (tidal volume of 3‐4 ml/kg, respiratory rate of 10‐12 bpm, PEEP of 5‐8 cmH2O, FiO2 30%)
Study: 34611042
Drug: Partial oral
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial oral antibiotic treatment
Study: 38960907
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 48 weeks
Study: 32468672
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg bid
Study: 35132875
Drug: Conventional P2Y12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional P2Y12 inhibitor selection
Study: 35695197
Drug: Constraint‐Induced Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐Induced Movement therapy
Study: 34083234
Drug: Sequential androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential androgen receptor signaling inhibitors (abiraterone and enzalutamide)
Study: 39312389
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy interventions
Study: 33470732
Drug: Isometric handgrip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric handgrip training (five times weekly)
Study: 33196410
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control group
Study: 34901997
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP), approximately 250 mL
Study: 36196738
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) training consisting of six sessions
Study: 37689749
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy
Study: 33459082
Drug: Computerized neurocognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized neurocognitive testing (CNT) administered after maximal physical exertion (MPE) at recovery intervals of Immediate, 10-minutes, and 20-minutes
Study: 33459082
Drug: Computerized neurocognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized neurocognitive testing (CNT) administered after maximal physical exertion (MPE) at a 20-minute recovery interval
Study: 33894370
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir therapy (AVT)
Study: 33894370
Drug: AVT +
Normalized name: Avtozma
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT + adjunctive PDT
Study: 35030333
Drug: Erdafitinib 8
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erdafitinib 8 mg/day UpT regimen
Study: 35843287
Drug: CF only
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF only for 18 hours before CE and simethicone 200mg in 150 ml water immediately prior to CE
Study: 34424868
Drug: Cost-cutting measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-cutting measures (older-generation implants)
Study: 35195344
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (exercise routines three times weekly and once weekly on discharge for 6 weeks supervised by a physical therapist)
Study: 34624497
Drug: Tailored chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored chemotherapy (T)
Study: 34624497
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy (C)
Study: 36905736
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration
Study: 35501519
Drug: Laser monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser monotherapy
Study: 34232082
Drug: Capsule containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing BB‐12 (CAP)
Study: 36205099
Drug: 50000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50000 IU/day intramuscular vitamin A for a maximum of two weeks
Study: 36205099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued their common treatment protocols
Study: 33048456
Drug: Glecaprevir/Pibrentasvir (GLE/PIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/Pibrentasvir (GLE/PIB) 300/120 mg
Study: 35534184
Drug: Hydrocortisone (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (cumulative dose 72.5 mg/kg)
Study: 32408396
Drug: Methylation-L
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylation-L
Study: 32635661
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation
Study: 36506775
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg midazolam
Study: 32241084
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with TPF (docetaxel & cisplatin 75 mg/m2 on D1, and fluorouracil 75 mg/m2 on D1-4) followed by CRT (cisplatin 100 mg/m2 on D1 3-weekly, two times plus radiotherapy 68.4 Gy/30 fractions)
Study: 35733373
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (5000 IU daily for 4 months)
Study: 35733373
Drug: Placebo (topiramate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (topiramate with placebo capsule)
Study: 35340223
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (Mosapride citrate tablets)
Study: 34159294
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months adjuvant chemotherapy
Study: 34159294
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months adjuvant chemotherapy
Study: 36423412
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy (ICBT)
Study: 32037021
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (12 sessions lasting 2 hours each, 3 follow-up monthly sessions, and 1 closing session)
Study: 37591293
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg every 3 weeks
Study: 36308296
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy
Study: 35948209
Drug: Monthly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly treatment with pegcetacoplan
Study: 35948209
Drug: Every-other-month (EOM)
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every-other-month (EOM) treatment with pegcetacoplan
Study: 34274500
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA)
Study: 32013958
Drug: Dapoxetine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine treatment for 4 weeks
Study: 35005013
Drug: oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxycodone
Study: 35167133
Drug: Paraffin cream
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin cream (PC)
Study: 38985161
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg
Study: 36782093
Drug: Sotagliflozin 200
Normalized name: sotagliflozin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin 200 mg
Study: 34117737
Drug: Tocilizumab monotherapy
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab monotherapy
Study: 34390083
Drug: Amoxicillin-levofloxacin (AL)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-levofloxacin (AL) quadruple therapy (amoxicillin 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, tripotassium dicitrato bismuthate 300 mg QID)
Study: 34390083
Drug: Tetracycline-levofloxacin (TL)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline-levofloxacin (TL) quadruple therapy
Study: 34390083
Drug: Amoxicillin-levofloxacin (AL)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-levofloxacin (AL) quadruple therapy
Study: 33393112
Drug: Lanreotide depot/autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide depot/autogel 120 mg every 4 weeks (LAN)
Study: 34104096
Drug: Planox® lemon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planox® lemon verbena extract (LVE) 400 mg/human/day
Study: 33789735
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable soft contact lenses (SCLs)
Study: 34821020
Drug: Hetrombopag (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag (2.5, 3.75, 5, or 7.5 mg once daily) during Stage 4
Study: 35177277
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice chemotherapy (CT) in PSOC
Study: 35177277
Drug: Olaparib (OLA)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (OLA) monotherapy in PROC
Study: 35177277
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice chemotherapy (CT) in PROC
Study: 35177277
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice chemotherapy (CT) in BRCA-wildtype PROC
Study: 33832406
Drug: Aripiprazole at
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole at a dose of up to 20 mg daily
Study: 33832406
Drug: Quetiapine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine at a dose of up to 600 mg daily
Study: 33832406
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at a dose of up to 30 mg daily
Study: 32074243
Drug: Neurohormonal antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neurohormonal antagonists
Study: 34324783
Drug: Corticosteroids administered
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids administered to PWH (33.3%)
Study: 33645135
Drug: Shenxiong Injection
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenxiong Injection combined with conventional treatment